Patents by Inventor Robert H. Gruninger

Robert H. Gruninger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1,2,4-triazolylaminoaryl (heteroaryl) sulfonamide derivatives
    Patent number: 8299082
    Abstract: 1,2,4-Triazolylaminoaryl(heteroaryl)sulfonamide derivatives of formula (I), pharmaceutically acceptable salts thereof, processes for the manufacture of 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives and pharmaceutical compositions containing 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives are disclosed: The 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives of formula (I) possess cell cycle inhibitory activity and are accordingly useful for their anti cell proliferation (such as anti cancer) activity.
    Type: Grant
    Filed: September 29, 2010
    Date of Patent: October 30, 2012
    Assignee: Janssen Pharmaceutica, N.V.
    Inventors: Shenlin Huang, Ronghui Lin, Peter J. Connolly, Stuart L. Emanuel, Steven A. Middleton, Robert H. Gruninger, Steven K. Wetter
  • 1,2,4-TRIAZOLYLAMINOARYL (HETEROARYL) SULFONAMIDE DERIVATIVES
    Publication number: 20110077249
    Abstract: 1,2,4-Triazolylaminoaryl(heteroaryl)sulfonamide derivatives of formula (I), pharmaceutically acceptable salts thereof, processes for the manufacture of 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives and pharmaceutical compositions containing 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives are disclosed: The 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives of formula (I) possess cell cycle inhibitory activity and are accordingly useful for their anti cell proliferation (such as anti cancer) activity.
    Type: Application
    Filed: September 29, 2010
    Publication date: March 31, 2011
    Applicant: Janssen Pharmaceutica N.V.
    Inventors: Shenlin Huang, Ronghui Lin, Peter J. Connolly, Stuart L. Emanuel, Steven A. Middleton, Robert H. Gruninger, Steven K. Wetter
  • 1,2,4-Triazolylaminoaryl (heteroaryl) sulfonamide derivatives
    Patent number: 7888380
    Abstract: 1,2,4-Triazolylaminoaryl(heteroaryl)sulfonamide derivatives of formula (I), pharmaceutically acceptable salts thereof, processes for the manufacture of 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives and pharmaceutical compositions containing 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives are disclosed: The 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives of formula (I) possess cell cycle inhibitory activity and are accordingly useful for their anti cell proliferation (such as anti cancer) activity.
    Type: Grant
    Filed: October 6, 2005
    Date of Patent: February 15, 2011
    Assignee: Janssen Pharmaceutica, N.V.
    Inventors: Shenlin Huang, Ronghui Lin, Peter J. Connolly, Stuart L. Emanuel, Steven A. Middleton, Robert H. Gruninger, Steven K. Wetter
  • Substituted triazole diamine derivatives as kinase inhibitors
    Patent number: 7317031
    Abstract: The present invention provides substituted triazole diamine derivatives as selective kinase or dual-kinase inhibitors and a method for treating or ameliorating a selective kinase or dual-kinase mediated disorder.
    Type: Grant
    Filed: February 1, 2005
    Date of Patent: January 8, 2008
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Ronghui Lin, Shenlin Huang, Steven K. Wetter, Peter J. Connolly, Stuart L. Emanuel, Robert H. Gruninger, Steven A. Middleton
  • Amino substituted pyridinyl methanone compounds useful in treating kinase disorders
    Patent number: 7109220
    Abstract: The present invention provides amino substituted pyridinyl methanone compounds; pharmaceutical compositions comprising the compounds and methods of synthesis thereof. The compounds, which are cyclin dependent kinase (CDK) inhibitors, can be used to treat or ameliorate CDK mediated disorders. The invention thus also provides the therapeutic or prophylactic use of the compounds and/or pharmaceutical compositions to treat such disorders.
    Type: Grant
    Filed: November 4, 2004
    Date of Patent: September 19, 2006
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Ronghui Lin, Steven K. Wetter, Yanhua Lu, Peter J. Connolly, Stuart Emanuel, Robert H. Gruninger, Steven A. Middleton
  • Substituted triazole diamine derivatives as kinase inhibitors
    Patent number: 6924302
    Abstract: The present invention provides substituted triazole diamine derivatives as selective kinase or dual-kinase inhibitors and a method for treating or ameliorating a selective kinase or dual-kinase mediated disorder.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: August 2, 2005
    Assignee: Ortho McNeil Pharmaceutical, Inc.
    Inventors: Ronghui Lin, Peter J. Connolly, Steven K. Wetter, Shenlin Huang, Stuart L. Emanuel, Robert H. Gruninger, Steven A. Middleton
  • Substituted triazole diamine derivatives as kinase inhibitors
    Publication number: 20040077699
    Abstract: The present invention provides substituted triazole diamine derivatives as selective kinase or dual-kinase inhibitors and a method for treating or ameliorating a selective kinase or dual-kinase mediated disorder.
    Type: Application
    Filed: December 21, 2001
    Publication date: April 22, 2004
    Inventors: Ronghui Lin, Peter J. Connolly, Steven K. Wetter, Shenlin Huang, Stuart L. Emanuel, Robert H. Gruninger, Steve A. Middleton